IDEAYA Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-113.7	-274.48	-112.96	-58.66	-49.76
Depreciation & Amortization	4.59	3.83	4.01	3.52	3.03
Stock-Based Compensation	46.12	34.75	18.49	11.63	8.24
Other Adjustments	-9.98	-23.23	-11.55	-0.7	1.83
Change in Receivables	-	-	0.19	0.89	0.77
Changes in Accounts Payable	2.7	8.28	2.64	1.86	1.17
Changes in Accrued Expenses	10.43	10.79	1.64	4.57	4.21
Changes in Unearned Revenue	-5.97	-	-13.75	-46.48	-23.54
Changes in Other Operating Activities	-5.28	-7.53	-3.92	-3.82	-1.73
Operating Cash Flow	-71.1	-247.58	-115.22	-87.18	-55.78
Capital Expenditures	-2.37	-3.86	-2.37	-3.44	-2.64
Purchases of Investments	-607.89	-1,191	-595.98	-255.81	-315
Proceeds from Sale of Investments	680.23	692.61	439.89	225.85	247.97
Investing Cash Flow	69.98	-502.56	-158.46	-33.4	-69.67
Issuance of Common Stock	29.78	677.55	362.72	97.17	145.45
Net Common Stock Issued (Repurchased)	29.78	677.55	362.72	97.17	145.45
Financing Cash Flow	29.78	677.55	362.72	97.17	145.45
Net Cash Flow	28.66	-72.59	89.04	-23.41	20.01
Free Cash Flow	-73.47	-251.44	-117.59	-90.62	-58.42
FCF Margin	-33.59%	-3592.01%	-502.85%	-177.92%	-209.09%
Free Cash Flow Per Share	-0.83	-3.08	-2.04	-2.19	-1.66
Levered Free Cash Flow	-109.61	-262.95	-124.72	-102.44	-69.27
Unlevered Free Cash Flow	-155.22	-315.45	-146.19	-106.29	-69.77

Updated Feb 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q